| Literature DB >> 29136510 |
Carolyn D Hurst1, Olivia Alder1, Fiona M Platt1, Alastair Droop2, Lucy F Stead3, Julie E Burns1, George J Burghel4, Sunjay Jain5, Leszek J Klimczak6, Helen Lindsay4, Jo-An Roulson7, Claire F Taylor2, Helene Thygesen2, Angus J Cameron8, Anne J Ridley9, Helen R Mott10, Dmitry A Gordenin11, Margaret A Knowles12.
Abstract
Bladder cancer incurs a higher lifetime treatment cost than other cancers due to frequent recurrence of non-invasive disease. Improved prognostic biomarkers and localized therapy are needed for this large patient group. We defined two major genomic subtypes of primary stage Ta tumors. One of these was characterized by loss of 9q including TSC1, increased KI67 labeling index, upregulated glycolysis, DNA repair, mTORC1 signaling, features of the unfolded protein response, and altered cholesterol homeostasis. Comparison with muscle-invasive bladder cancer mutation profiles revealed lower overall mutation rates and more frequent mutations in RHOB and chromatin modifier genes. More mutations in the histone lysine demethylase KDM6A were present in non-invasive tumors from females than males.Entities:
Keywords: KDM6A; RHOB; bladder cancer; gender; genomics; mTORC1; metabolism; recurrence-free survival; subtypes
Mesh：
Substances：
Year: 2017 PMID： 29136510 PMCID： PMC5774674 DOI： 10.1016/j.ccell.2017.08.005
Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743